STA
IMUX icon

Summit Trail Advisors’s Immunic IMUX Stock Holding History

Summit Trail Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,160
Closed -$24K – 736
2024
Q2 		$24K Buy
2,160
+300
+16% +$3.73K ﹤0.01% 612
2024
Q1 		$24.6K Buy
+1,860
New +$24.2K ﹤0.01% 603

Other funds holding IMUX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Trail Advisors's IMUX Position: Q3 2024 in Review

Summit Trail Advisors sold out of Immunic (IMUX) in Q3 2024, closing a stake of 2,160 shares — an estimated $24K sold.

Summit Trail Advisors first reported a position in IMUX in Q1 2024 and held it in 2 quarters. The position peaked at $24.6K in Q1 2024. 61 funds tracked by Wall St. Rank hold IMUX as of Q3 2024.

  • Summit Trail Advisors reported no remaining Immunic position as of Q3 2024 after selling out during the quarter.
  • Summit Trail Advisors sold 2,160 Immunic shares in Q3 2024, an estimated $24K.
  • Summit Trail Advisors first reported a position in Immunic in Q1 2024 and held it in 2 quarters.
  • Summit Trail Advisors's Immunic position peaked at $24.6K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Immunic as of Q3 2024.

Based on Summit Trail Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.